G01N 2333/96416
Aspartic endopeptidases
Official title: Aspartic endopeptidases (3.4.23)
G01N2333/96416 (Aspartic endopeptidases) appears on 10 US grants and 19 published applications in this corpus.
Search patents in G01N- Granted patents
- 10
- Published applications
- 19
- Assignees
- 13
- Inventors
- 70
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 3 | 0 |
| 2024 | 0 | 6 |
| 2025 | 2 | 4 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of characterizing and purifying VEGF receptor fusion protein25 Aug 2026US 12,715,905 B2Regeneron Pharmaceuticals, Inc.
- Phospho-tau antibodies and methods of use24 Jun 2025US 12,339,290 B2Alzpath, Inc.
- Phospho-TAU antibodies and methods of use15 Apr 2025US 12,276,671 B2Alzpath, Inc.
- Method for evaluating metabolizable energy in goose diet by using a simulative digestion gross energy technique14 Nov 2023US 11,817,181 B2South China Agricultural University
- Methods for quantifying drug concentration in a prodrug composition24 Oct 2023US 11,796,546 B2Genzyme Corporation
- Method and device for predicting significant gastric aspiration and lung transplant outcome30 Jul 2026US 2026/0219272 A1University Health Network
- Methods of characterizing and purifying vegf receptor fusion protein1 Jan 2026US 2026/0001935 A1Regeneron Pharmaceuticals, Inc.
- Phospho-tau antibodies and methods of use4 Sep 2025US 2025/0277799 A1Alzpath, Inc.
- Spatially identifying nucleic acids that interact with proteins17 Jul 2025US 2025/0230498 A1
- Methods of characterizing and purifying vegf receptor fusion protein26 Jun 2025US 2025/0206803 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents